In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consumer protection bill

This article was originally published in The Rose Sheet

Executive Summary

HR 2621 moves to the Senate after passing lower chamber June 11 by voice vote. Measure would amend the Federal Anti-Tampering Act by making it a crime to "knowingly stamp, print, place or insert any writing in or on any consumer product...prior to its sale" without the consent of the product's manufacturer, distributor or retailer. Consumer Product Protection Act of 2002, introduced last July by Rep. Melissa Hart (D-Penn.) and amended May 8, was spurred by recent product tampering cases primarily in the food industry. Speaking about the bill, Rep. Tammy Baldwin (D-Wisc.) notes "it has become clear that law enforcement officials lack the authority to prosecute these crimes under state or federal law." The Cosmetic, Toiletry & Fragrance Association supports the bill...

You may also be interested in...

FDA Slams Teligent For Lax Approach To Complaint Handling And Stability Testing

Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.

Device Week, 12 December 2019 – Global Insulin Pump Market Will Face Fierce Rivalry Among Major Players In 2020

In this edition of Device Week, Medtech Insight's deputy editor Reed Miller chats with managing editor Marion Webb about her latest in-depth Market Intel story, the first part of a two-part series focusing on the competitive landscape of the global insulin pump market.

Can COMPASS Bring Psilocybin’s ‘Magic’ To Depression?

COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its CEO tells Scrip.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts